BOOKS BY CATEGORY
Your Account
Handbook of HER2-targeted agents in breast cancer
Price
Quantity
€43.91
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15-25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies.
Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.


Contents:

Introduction and background biology.- HER2 testing.- HER2-positive breast cancer: adjuvant and neoadjuvant therapy.- HER2-positive metastatic breast cancer: first-line treatment.- HER2-positive metastatic breast cancer: second-line treatment.- Emerging targeted agents for HER2-positive breast cancer.


PRODUCT DETAILS

ISBN-13: 9781907673931
Publisher: Springer (Springer Healthcare)
Publication date: November, 2014
Pages: 96
Weight: 1238g
Availability: Available
Subcategories: Diseases and Disorders, General Practice, Oncology, Pharmacology

CUSTOMER REVIEWS

Average Rating